Danaher Co. (NYSE:DHR) Shares Purchased by Napean Trading & Investment Co Singapore PTE Ltd

Napean Trading & Investment Co Singapore PTE Ltd grew its position in Danaher Co. (NYSE:DHR) by 52.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,497 shares of the conglomerate’s stock after purchasing an additional 19,193 shares during the quarter. Danaher makes up 3.2% of Napean Trading & Investment Co Singapore PTE Ltd’s investment portfolio, making the stock its 11th largest position. Napean Trading & Investment Co Singapore PTE Ltd’s holdings in Danaher were worth $12,739,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DHR. Heck Capital Advisors LLC purchased a new position in shares of Danaher during the 4th quarter worth approximately $27,000. Decker Retirement Planning Inc. acquired a new stake in shares of Danaher during the fourth quarter valued at $31,000. Golden State Wealth Management LLC acquired a new position in shares of Danaher in the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher in the third quarter valued at $39,000. Finally, Pineridge Advisors LLC boosted its position in shares of Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after acquiring an additional 57 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 11.10% of the stock is currently owned by company insiders.

Danaher Trading Up 0.7 %

Shares of DHR stock opened at $211.63 on Monday. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a 50-day moving average of $217.46 and a 200-day moving average of $238.50. The stock has a market cap of $151.26 billion, a price-to-earnings ratio of 40.08, a PEG ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the firm earned $2.09 earnings per share. On average, equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 annualized dividend and a yield of 0.60%. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is currently 24.24%.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of recent analyst reports. Citigroup decreased their price target on shares of Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Scotiabank started coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Raymond James reaffirmed a “market perform” rating on shares of Danaher in a research note on Monday, February 3rd. Robert W. Baird lowered their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $277.00 price objective (down previously from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $278.24.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.